IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39557863.
- Also identified by DOI 10.1038/s41467-024-54420-w and PMC identifier 11574270.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Blockade of NKG2A/HLA-E interaction is a promising strategy to unleash the anti-tumor response. Yet the role of NKG2A<sup>+</sup> CD8 T cells in the anti-tumor response and the regulation of NKG2A expression on human tumor-infiltrating T cells are still poorly understood. Here, by performing CITE-seq on T cells derived from head and neck squamous cell carcinoma and colorectal cancer, we show that NKG2A expression is induced on CD8 T cells differentiating into cytotoxic, CD39<sup>+</sup>CD103<sup>+</sup> double positive (DP) cells, a phenotype associated with tumor-reactive T cells. This developmental trajectory leads to TCR repertoire overlap between the NKG2A<sup>-</sup> and NKG2A<sup>+</sup> DP CD8 T cells, suggesting shared antigen specificities. Mechanistically, IL-12 is essential for the expression of NKG2A on CD8 T cells in a CD40/CD40L- dependent manner, in conjunction with TCR stimulation. Our study thus reveals that NKG2A is induced by IL-12 on human tumor-reactive CD8 T cells exposed to a TGF-β-rich environment, highlighting an underappreciated immuno-regulatory feedback loop dependent on IL-12 stimulation.
Medical subject headings
- NK Cell Lectin-Like Receptor Subfamily C
- CD8-Positive T-Lymphocytes
- Interleukin-12